For Immediate Release
Chicago, IL – October 05, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Loncar Cancer Immunotherapy ETF (Nasdaq:CNCR – Free Report), First Trust Mid Cap Growth AlphaDEX Fund (Nasdaq:FNY – Free Report), iShares Dow Jones Transportation Average Index Fund (BATS:IYT – Free Report), iShares Edge MSCI Multifactor Global ETF (NYSEARCA:ACWF – Free Report) and Barron's 400 ETF (NYSEARCA:BFOR – Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday’s Analyst Blog:
5 ETF Picks for October
The month of October will be highlighted by a deluge of earnings and investors’ quest for clarity on the Fed’s likely policy tightening as well as passage of tax reforms. As per the Earnings Trends issued on Sep 27, 2017, earnings growth of the S&P 500 in Q3 is expected to be 3.2% on 5% higher revenues. Third-quarter revenue growth is projected to be way higher than 2.2% in Q3 of 2016 while earnings growth might come in slightly lower than what we saw (4%) in the year-ago cycle.
The economic front looks upbeat as evident by the 13-year high manufacturing activity recorded in September and a jump in new auto sales. The broader market has also seen a decent start in October, though many fear disturbingly low levels of volatility and chances of a crash if Trump fails to push through the tax reform.
Against this backdrop, it is important to pin point ETFs that could safeguard investors from any sudden market swing as well as play the current momentum.
Loncar Cancer Immunotherapy ETF(Nasdaq:CNCR – Free Report)
This can be a great momentum play. Biotech ETFs especially those with a focus on cancer therapy are on fire lately on a slew of mergers and acquisitions, FDA’s approval of CAR-T cell therapy and improving research and developments.
Shares of Endocyte soared more than 150% on Oct 2, after it acquired an exclusive worldwide license to develop and commercialize ABX GmbH’s phase III-ready prostate cancer candidate 177Lu-PSMA-617. There was Gilead’s buyout announcement of the clinical-stage biopharmaceutical company Kite Pharma. The FDA has in fact given its nod to 34 drugs so far in 2017 including three in September. This is already way higher than 22 approvals seen last year.
First Trust Mid Cap Growth AlphaDEX Fund(Nasdaq:FNY – Free Report)
With both the United States and global economy on the rise, it is time to play mid-cap growth ETFs like FNY. This is because the greenback may gain strength in the coming days on an improving U.S. economy. This will go against large-cap stocks with greater foreign exposure. But through md-cap growth ETFs, investors can mitigate the adverse impact of a rising dollar while tap the surge in the global economy alongside.
iShares Dow Jones Transportation Average Index Fund(BATS:IYT – Free Report)
As per the source, Dow Jones Transportation index enjoys a seasonal tailwind in October. Plus, the transportation sector is expected to witness revenue growth of 4.6% in the ongoing reporting cycle, after 10.1% growth in Q2. The transportation sector is best positioned to take advantage of falling crude. This is especially true as energy costs form a major portion of the overall costs of this sector (read: 5 Sector ETFs for Revenue Growth Play).
If this was not enough, airline stocks surged on Oct 3 following Cowen & Co. analyst Helane Becker’s reiteration of an outperform rating on Delta Airlines (DAL). The analyst sees Delta’s outlook ‘positive,’ as per an article published on MarketWatch. The surge benefited the transportation ETF. Also, the fund should offer some bargains now as these stocks were battered in previous months on back-to-back hurricanes (read: Top and Flop Sector ETFs of Q3).
iShares Edge MSCI Multifactor Global ETF(NYSEARCA:ACWF – Free Report)
A look at global ETFs is also warranted given the upbeat prospects. This way, investors can mitigate certain risks. And the fund looks to track the global developed and emerging market large- and mid-cap stocks chosen on the basis of value, quality, momentum and low-size scores (read: Global Dividend Payments Upbeat in Q2: ETFs to Benefit).
Barron's 400 ETF(NYSEARCA:BFOR – Free Report)
This ETF seeks to track the performance of the rules-based and fundamentals-driven Barron’s 400 Index. The benchmark looks to select high performing U.S. stocks based on four fundamental factors — growth, valuation, profitability and cash flow. The fund will suit investors seeking quality exposure (read: Are We Nearing a Bear Market? ETFs to Lean On).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Get the full Report on CNCR - FREE
Get the full Report on FNY - FREE
Get the full Report on IYT - FREE
Get the full Report on ACWF - FREE
Get the full Report on BFOR - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ISHARS-TRAN AVG (IYT): ETF Research Reports
LONCAR CANCER (CNCR): ETF Research Reports
ISHARS-FS GLBL (ACWF): ETF Research Reports
FT-MC GROWTH AD (FNY): ETF Research Reports
BARRONS-400 ETF (BFOR): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research